High-dose glycine inhibits the loudness dependence of the auditory evoked potential (LDAEP) in healthy humans

RationaleThe loudness dependence of the auditory evoked Potential (LDAEP) has been suggested to be a putative marker of central serotonin function, with reported abnormalities in clinical disorders presumed to reflect serotonin dysfunction. Despite considerable research, very little is known about the LDAEP’s sensitivity to other neurotransmitter systems.ObjectivesGiven the role of N-methyl-d-aspartate (NMDA) receptors in modulating pyramidal cell activity in cortico-cortico and thalamo-cortical loops, we examined the effect of targeting the glycine modulatory site of the NMDA receptor with high-dose glycine on the LDAEP in healthy subjects.Materials and methodsThe study was a double-blind, placebo-controlled repeated-measures design in which 14 healthy participants were tested under two acute treatment conditions, placebo and oral glycine (0.8 g/kg). Changes in the amplitude of the N1/P2 at varying intensities (60, 70, 80, 90, 100 dB) were examined at CZ.ResultsCompared to placebo, high-dose glycine induced a weaker LDAEP (a pronounced decrease in the slope of the N1/P2 with increasing tone loudness; p < 0.02).ConclusionWhile the exact mechanism responsible for the effects of glycine on the LDAEP are not known, the findings suggest an inhibitory effect in the cortex, possibly via activation of NMDA receptors on GABA interneurons or inhibitory glycine receptors. The findings add to the growing literature exhibiting modulation of the LDAEP by multiple neurochemical systems in addition to the serotonergic system.

[1]  Georg Juckel,et al.  Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: A new hypothesis , 1993, Biological Psychiatry.

[2]  L. Knorring,et al.  Biochemistry of the augmenting-reducing response in visual evoked potentials. , 1981, Neuropsychobiology.

[3]  David A Lewis,et al.  Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. , 2006, Archives of neurology.

[4]  M. Martina,et al.  Glycine transporter type 1 blockade changes NMDA receptor‐mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels , 2004, The Journal of physiology.

[5]  Valéria Csépe,et al.  Auditory Evoked Potentials Reflect Serotonergic Neuronal Activity—A Study in Behaving Cats Administered Drugs Acting on 5-HT1A Autoreceptors in the Dorsal Raphe Nucleus , 1999, Neuropsychopharmacology.

[6]  R. Croft,et al.  The cognitive effects of modulating the glycine site of the NMDA receptor with high‐dose glycine in healthy controls , 2008, Human psychopharmacology.

[7]  Daniel Senkowski,et al.  Allelic Variants of the Functional Promoter Polymorphism of the Human Serotonin Transporter Gene is Associated with Auditory Cortical Stimulus Processing , 2003, Neuropsychopharmacology.

[8]  J. Coyle,et al.  The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia , 2004, Psychopharmacology.

[9]  G. Juckel,et al.  Is the loudness dependence of auditory evoked potentials modulated by the selective serotonin reuptake inhibitor citalopram in healthy subjects? , 2006, Human psychopharmacology.

[10]  J. Coyle,et al.  Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. , 1999, The American journal of psychiatry.

[11]  M. Roux,et al.  Neuronal and Glial Glycine Transporters Have Different Stoichiometries , 2000, Neuron.

[12]  M. Buchsbaum,et al.  Individual differences in stimulus intensity response. , 1971, Psychophysiology.

[13]  T. Branchek,et al.  Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors , 1992, Neuron.

[14]  C. Rampon,et al.  Distribution of glycine-immunoreactive cell bodies and fibers in the rat brain , 1996, Neuroscience.

[15]  Jürgen Gallinat,et al.  The serotonin syndrome scale: first results on validity , 1998, European Archives of Psychiatry and Clinical Neuroscience.

[16]  J. Kirsch.  Glycinergic transmission , 2006, Cell and Tissue Research.

[17]  R. Snell,et al.  Distribution of gephyrin in the human brain: an immunohistochemical analysis , 2003, Neuroscience.

[18]  D. Javitt,et al.  Adjunctive high-dose glycine in the treatment of schizophrenia. , 2001, The international journal of neuropsychopharmacology.

[19]  W Zieglgänsberger,et al.  Glutamate receptors form hot spots on apical dendrites of neocortical pyramidal neurons. , 2001, Journal of neurophysiology.

[20]  Georg Juckel,et al.  Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity , 2003, Schizophrenia Research.

[21]  P. Jonas,et al.  Corelease of two fast neurotransmitters at a central synapse. , 1998, Science.

[22]  P. Ascher,et al.  Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. , 1998, Journal of neurophysiology.

[23]  S. Fahn,et al.  Therapeutic trial with glycine in myoclonus , 1988, Movement disorders : official journal of the Movement Disorder Society.

[24]  C. Parsons,et al.  Modulation of NMDA receptors by glycine — introduction to some basic aspects and recent developments , 2005, Amino Acids.

[25]  M. Pangalos,et al.  Neurotransmitter receptors of rat cortical pyramidal neurones: implications for in vivo imaging and therapy. , 1993, Journal of reproduction and fertility. Supplement.

[26]  S Debener,et al.  Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[27]  M. Millan.  N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives , 2005, Psychopharmacology.

[28]  D. Javitt,et al.  Modulation of Striatal Dopamine Release by Glycine Transport Inhibitors , 2005, Neuropsychopharmacology.

[29]  C. Parsons,et al.  Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. , 1998, Pharmacological reviews.

[30]  H. Möller,et al.  Serotonin and Dopamine Transporter Availabilities Correlate with the Loudness Dependence of Auditory Evoked Potentials in Patients with Obsessive-Compulsive Disorder , 2004, Neuropsychopharmacology.

[31]  M J Campbell,et al.  The monoaminergic innervation of primate neocortex. , 1986, Human neurobiology.

[32]  U. Heinemann,et al.  Characterization of the inhibitory glycine receptor on entorhinal cortex neurons , 2004, The European journal of neuroscience.

[33]  J. Krystal,et al.  Glycine Site Agonists of the NMDA Receptor: A Review , 1995 .

[34]  Baribeau Jc,et al.  The effect of selective attention on augmenting/intensity function of the early negative waves of AEPs. , 1987 .

[35]  Shih-Jen Tsai,et al.  Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression. , 2005, Journal of psychiatry & neuroscience : JPN.

[36]  H. Fibiger,et al.  Glutamate receptor agonists decrease extracellular dopamine in the rat nucleus accumbens in vivo , 1996, Synapse.

[37]  K. Lesch,et al.  Further Evidence for an Association of 5-HTTLPR with Intensity Dependence of Auditory-Evoked Potentials , 2006, Neuropsychopharmacology.

[38]  G. Stotz,et al.  The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression , 2000, Psychopharmacology.

[39]  G. V. Simpson,et al.  Multiple brain systems generating the rat auditory evoked potential. I. Characterization of the auditory cortex response , 1993, Brain Research.

[40]  Charles R. Yang,et al.  Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. , 2003, Journal of neurophysiology.

[41]  S. Grossberg,et al.  Neural dynamics of decision making under risk: affective balance and cognitive-emotional interactions. , 1988, Psychological review.

[42]  D. Javitt,et al.  Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial , 1996, Biological Psychiatry.

[43]  F. Nuttall,et al.  The metabolic response to ingested glycine. , 2002, The American journal of clinical nutrition.

[44]  K. Phan,et al.  Dopamine receptor stimulation does not modulate the loudness dependence of the auditory evoked potential in humans , 2006, Psychopharmacology.

[45]  J. Krystal,et al.  IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans , 2000, Biological Psychiatry.

[46]  D. Senkowski,et al.  Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder , 2003, Biological Psychiatry.

[47]  Connolly Jf.  ERPs suggest the importance of subcortical mechanisms in activities typically associated with cortical functions. , 1987 .

[48]  Jörg Daumann,et al.  High Intensity Dependence of Auditory Evoked Dipole Source Activity Indicates Decreased Serotonergic Activity in Abstinent Ecstasy (MDMA) Users , 2000, Neuropsychopharmacology.

[49]  U Hegerl,et al.  Event-related potentials: Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? , 2001 .

[50]  R. Barry,et al.  EOG correction of blinks with saccade coefficients: a test and revision of the aligned-artefact average solution , 2000, Clinical Neurophysiology.

[51]  R. Croft,et al.  Is the Loudness Dependence of the Auditory Evoked Potential a Sensitive and Selective In Vivo Marker of Central Serotonergic Function? , 2005, Neuropsychopharmacology.

[52]  Heinrich Betz,et al.  Modulation of glycine receptor function: a novel approach for therapeutic intervention at inhibitory synapses? , 2002, Trends in pharmacological sciences.

[53]  M. Carrillo-de-la-Peña.  Effects of intensity and order of stimuli presentation on AEPs: an analysis of the consistency of EP augmenting/reducing in the auditory modality , 1999, Clinical Neurophysiology.

[54]  J. Connolly.  ERPs suggest the importance of subcortical mechanisms in activities typically associated with cortical functions. , 1987, Electroencephalography and clinical neurophysiology. Supplement.

[55]  P. Goldman-Rakic,et al.  The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. , 1994, Journal of neurophysiology.

[56]  J. Seamans,et al.  Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopamine in the Prefrontal Cortex , 1999, Neuropsychopharmacology.

[57]  T. Baldeweg,et al.  Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users. , 2001, The American journal of psychiatry.

[58]  Heinrich Betz,et al.  Glycine receptors: recent insights into their structural organization and functional diversity , 2006, Journal of neurochemistry.

[59]  F. Ratliff,et al.  The role of GABA-mediated intracortical inhibition in the generation of visual evoked potentials , 1986 .

[60]  G. Karmos,et al.  Auditory-evoked potentials as indicator of brain serotonergic activity first evidence in behaving cats , 1997, Biological Psychiatry.

[61]  K. Phan,et al.  Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function , 2006, Human psychopharmacology.

[62]  Karl Zilles,et al.  Glycine receptor immunoreactivity in rat and human cerebral cortex , 1991, Brain Research.

[63]  D. Javitt,et al.  Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.